Journal of Antimicrobial Chemotherapy · 2019 · 23 citations · 15 references
Life SciencesImmunologyInfectious DiseasesClinical ImmunologyInfectious Disease PharmacotherapyVirologyAntiretroviral TherapyAntiviral PharmacologyHuman Immunodeficiency Virus PharmacotherapyPredictive Marker AssessmentSustained Virologic Response DurationTherapy FailureTriple Combination Therapy
BACKGROUND: The gold standard for HIV-1 treatment is to administer triple antiretroviral therapy, but a shift to simplified regimens is being explored. Boosted darunavir monotherapy can be considered for patients who are for specific reasons not good candidates for dual or triple therapy. Still, a number of patients fail virologically or need to switch treatment. OBJECTIVES: To identify predictive markers for those patients that are more likely to sustain virological control under monotherapy, virological and immunological markers were explored in HIV-1-positive patients that experienced virological failure on ritonavir-boosted darunavir monotherapy in the PROTEA trial. METHODS: As a retrospective nested study of the PROTEA study (NCT01448707), we analysed 77 HIV-1-infected patients who were on darunavir/ritonavir 800/100 mg monotherapy up to 96 weeks. Patients were appointed to three distinct cohorts based on viral loads (VLs): (i) undetectable VL after 96 weeks; (ii) very-low-level viraemia (5-39 copies/mL); and (iii) failing treatment. Total HIV-1 DNA, integrated HIV-1 DNA and 2-long terminal repeat circular HIV-1 DNA (2LTR circles) were measured in PBMCs at baseline, week 48 and week 96. RESULTS: Total HIV-1 DNA and integrated HIV-1 DNA at baseline differed significantly between patients who experienced virological failure on monotherapy (P < 0.01 and P < 0.001). Although a higher level of HIV-1 DNA was measured in failures, this marker by itself does not provide enough predictive value to prospectively predict virological failure in patients on monotherapy. CONCLUSIONS: HIV-1 reservoir markers correlate with therapy failure in ritonavir-boosted darunavir monotherapy. However, their role as a predictive marker combined with other markers in a routine clinical setting should be further explored.
15
Yasuhiro Koh, Hirotomo Nakata, Kenji Maeda et al. · Antimicrobial Agents and Chemotherapy · 2003 · 366 citations · Full text
Christine Katlama, Marc Antoine Valantin, Michèle Algarté-Génin et al. · AIDS · 2010 · 164 citations
Nathan Clumeck, Mark Nelson, Andrew Hill et al. · HIV Medicine · 2012 · 94 citations
Sidonie Lambert-Niclot, Philippe Flandre, Marc‐Antoine Valantin et al. · The Journal of Infectious Diseases · 2011 · 83 citations · Full text